New Analyst Forecast: $ARGX Given $1130 Price Target
Morgan Stanley analyst Sean Laaman set a $1130 price target for Argenx (ARGX). Over the past 6 months, 16 analysts have issued targets with a median of $1140. Institutional investors have shown mixed activity, with some increasing and others decreasing their positions.
How this was made

The 30-second read
Why it matters
The new $1,130 target suggests upward momentum but lacks a concrete catalyst, limiting immediate trade urgency.
Market read
Provides a modest bullish signal for ARGX; relevance is limited to investors following analyst forecasts.
What to watch
No mention of upcoming clinical trial results or regulatory milestones that could affect the stock.
Background
ARGX is a biotech firm tracked by analysts; price targets are frequently updated based on pipeline developments.
Ticker impact
Morgan Stanley analyst Sean Laaman set a new price target of $1,130 for ARGX, the first such target reported in this article.
likely upward pressure as investors price in the higher target
New target is above recent median and reflects analyst optimism; however, no concrete catalyst beyond the forecast.
Market effects
May influence biotech sector sentiment as analysts adjust expectations for similar companies.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The target could be overly optimistic if upcoming trial data disappoints.
Key entities
- AnalystSean Laaman
Morgan Stanley analyst who issued the price target.


